Observational Study: Stool Bank for Cancer Patients on Immunotherapy
This study is collecting stool samples from people with cancer, specifically non-small cell lung carcinoma and colorectal carcinoma, who are receiving immunotherapy like pembrolizumab. Researchers want to understand how the bacteria in your gut (gut microbiota) affect how well these cancer treatments work. By studying these samples, they hope to identify specific bacteria that help make treatments more effective. This information could lead to new ways to improve cancer care. The study aims to enroll 100 participants and will look at treatment response after 6-12 months.
- Study design
- This is an observational study, meaning you won't receive a new treatment. It involves 100 participants across two locations.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will look at your checkpoint inhibitor response between 6 and 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Development and Analysis of a Stool Bank for Cancer Patients
At a glance
Conditions
Where it's being run
2 sites across 2 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Checkpoint inhibitor response6-12 months
Response of the tumor to treatment, as evaluated by the iRECIST criteria